END-OF-LIFE CARE AND CLINICAL CHARACTERISTICS OF NONSURVIVOR CANCER PATIENTS WITH COVID-19

ABSTRACT

Despite having advanced baseline malignancies, most patients received a trial of aggressive intensive care management with life support before considering any EOL measures. At hospital admission, 56% of patients had poor predicted 3-month cancer survival, and the treatment goal was predominantly for life prolongation (53%). B Introduction/Hypothesis: b Data detailing the end-of-life care (EOL) in cancer patients with COVID-19 is scarce. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)